NX-01

NX-01 appears to be an investigational **recombinant human coagulation factor VIII** product being developed by Neoletix for **hemophilia A**. Publicly available information identifies it as Neoletix's flagship product and describes it as a highly expressed rhFVIII candidate intended to improve access to factor VIII replacement therapy. The available sources do not provide enough high-confidence detail to determine a precise molecular differentiation versus other recombinant factor VIII products, a formal nonproprietary name, or a clearly documented clinical-stage mechanism beyond factor VIII replacement in the coagulation cascade.